The group’s principle activity is to provide customized biomarker assays and reagents, instrumentation and software, contract services for quantitative biomarker analysis, and development of companion diagnostic assays. The group also improves efficiency and effectiveness across the entire drug development continuum by providing the first advanced platform capable of measuring biomarker concentration with sub-cellular resolution in tissue sections. The group’s services include drug discovery and development, disease detection and diagnosis, and clinical pathology and patient care. The group operates from United States.
